A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006)
Philippa Musoke(Centers for Disease Control and Prevention), J. Brooks Jackson(VA Tennessee Valley Healthcare System), Kevin Dransfield(Boehringer Ingelheim (United States)), Terry Elliott(Makerere University), Melissa Allen(Family Health International 360), Amal Murarka(Makerere University), Francis Mmiro(Makerere University), Danstan Bagenda(Makerere University), David L. Hom(Makerere University), Lynne Mofenson(Elizabeth Glaser Pediatric AIDS Foundation), Thomas R. Fleming(University of Washington), Scott R. Horton(Makerere University), Mary Glenn Fowler(Johns Hopkins University), Clemensia Nakabiito(Makerere University), Mark Mirochnick(Boston University), Laura Guay(Johns Hopkins University), Joseph Pav(Makerere University)
Cited by 217
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
|The Lancet|1999|1.7k
Targeted Anticytokine Therapy in Patients With Chronic Heart Failure
|Circulation|2004|1.2k